Six-Month Response to Delamanid Treatment in MDR TB Patients

Abstract

Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability and treatment response at 6 months.

Keywords

• Tuberculosis
• multidrug resistance
• delamanid
• drug therapy
• combination
• antitubercular agents